SYK Quote, Financials, Valuation and Earnings

Baxter International has a net margin of 11.15% compared to Stryker's net margin of 4.8%. Stryker's return on equity of 14.2% beat Baxter International's return on equity of -7.38%.

Stryker has a consensus price target of $422.71, signalling upside risk potential of 8.15%. On the other hand Baxter International has an analysts' consensus of $38.03 which suggests that it could grow by 34.05%. Given that Baxter International has higher upside potential than Stryker, analysts believe Baxter International is more attractive than Stryker.

Stryker has a beta of 0.915, which suggesting that the stock is 8.528% less volatile than S&P 500. In comparison Baxter International has a beta of 0.610, suggesting its less volatile than the S&P 500 by 38.958%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.85%. Baxter International offers a yield of 2.82% to investors and pays a quarterly dividend of $0.17 per share. Stryker pays 40.73% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.9B, which are larger than Baxter International quarterly revenues of $2.6B. Stryker's net income of $654M is higher than Baxter International's net income of $126M. Notably, Stryker's price-to-earnings ratio is 52.82x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.50x versus 1.22x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 11.15% compared to Stryker's net margin of 14.45%. Stryker's return on equity of 14.2% beat Boston Scientific's return on equity of 9.57%.

Stryker has a consensus price target of $422.71, signalling upside risk potential of 8.15%. On the other hand Boston Scientific has an analysts' consensus of $117.36 which suggests that it could grow by 13.74%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Stryker has a beta of 0.915, which suggesting that the stock is 8.528% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.85%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.9B, which are larger than Boston Scientific quarterly revenues of $4.7B. Stryker's net income of $654M is lower than Boston Scientific's net income of $674M. Notably, Stryker's price-to-earnings ratio is 52.82x while Boston Scientific's PE ratio is 75.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.50x versus 8.75x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 11.15% compared to Stryker's net margin of 30.99%. Stryker's return on equity of 14.2% beat Intuitive Surgical's return on equity of 15.82%.

Stryker has a consensus price target of $422.71, signalling upside risk potential of 8.15%. On the other hand Intuitive Surgical has an analysts' consensus of $581.45 which suggests that it could grow by 13.42%. Given that Intuitive Surgical has higher upside potential than Stryker, analysts believe Intuitive Surgical is more attractive than Stryker.

Stryker has a beta of 0.915, which suggesting that the stock is 8.528% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.249%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.85%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.9B, which are larger than Intuitive Surgical quarterly revenues of $2.3B. Stryker's net income of $654M is lower than Intuitive Surgical's net income of $698.4M. Notably, Stryker's price-to-earnings ratio is 52.82x while Intuitive Surgical's PE ratio is 75.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.50x versus 21.35x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of 11.15% compared to Stryker's net margin of -5.14%. Stryker's return on equity of 14.2% beat Integer Holdings's return on equity of 4.85%.

Stryker has a consensus price target of $422.71, signalling upside risk potential of 8.15%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 27%. Given that Integer Holdings has higher upside potential than Stryker, analysts believe Integer Holdings is more attractive than Stryker.

Stryker has a beta of 0.915, which suggesting that the stock is 8.528% less volatile than S&P 500. In comparison Integer Holdings has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.988%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.85%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.9B, which are larger than Integer Holdings quarterly revenues of $437.4M. Stryker's net income of $654M is higher than Integer Holdings's net income of -$22.5M. Notably, Stryker's price-to-earnings ratio is 52.82x while Integer Holdings's PE ratio is 55.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.50x versus 2.36x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.